BioScrip Inc  

(Public, NASDAQ:BIOS)   Watch this stock  
Find more results for BIOS
3.00
+0.01 (0.33%)
Real-time:   1:26PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.97 - 3.05
52 week 1.35 - 3.39
Open 3.00
Vol / Avg. 268,853.00/920,341.00
Mkt cap 382.55M
P/E     -
Div/yield     -
EPS -0.62
Shares 127.52M
Beta 0.19
Inst. own 88%
May 2, 2018
BioScrip Inc Annual Shareholders Meeting (Estimated) - 2:00PM EDT - Add to calendar
Mar 8, 2018
Q4 2017 BioScrip Inc Earnings Release - 9:30AM EST - Add to calendar
Mar 8, 2018
Q4 2017 BioScrip Inc Earnings Call - 9:00AM EST - Add to calendar
Dec 5, 2017
BioScrip Inc at Mizuho Investor Conference
Nov 29, 2017
BioScrip Inc at Bank of America Merrill Lynch Leveraged Finance Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -6.24% -3.67%
Operating margin 0.40% 0.21%
EBITD margin - 4.70%
Return on average assets -8.27% -6.04%
Return on average equity - -
Employees 2,039 -
CDP Score - -

Address

1600 Broadway Ste 950
DENVER, CO 80202-4970
United States - Map
+1-720-6975200 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Officers and directors

Daniel E. Greenleaf President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Stephen M. Deitsch Chief Financial Officer, Senior Vice President, Treasurer
Age: 45
Bio & Compensation  - Reuters
Harriet Booker Chief Operating Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Betty Y Jang Senior Vice President, Chief Compliance Officer
Age: 47
Bio & Compensation  - Reuters
Danny Claycomb Senior Vice President - Revenue Cycle Management
Bio & Compensation  - Reuters
Tony Lopez Vice President, Chief Accounting Officer, Controller
Age: 51
Bio & Compensation  - Reuters
Kathryn M. Stalmack General Counsel
Bio & Compensation  - Reuters
Scott J. Davido Chief Implementation Officer
Age: 48
Bio & Compensation  - Reuters
Michael G. Bronfein CPA Director
Age: 60
Bio & Compensation  - Reuters
Steven Neumann Director
Bio & Compensation  - Reuters